LIRA treatment in women with PCOS reduced levels of cardiovascular risk biomarkers MR-proANP by 25% and MR-proADM by 6% (borderline significance) compared with placebo. The decrease in MR-proANP was independently associated with an increase in the heart rate. Here, NPPA is linked to polycystic ovary syndrome.